Cidara Therapeutics
CDTX
Performance
About Cidara Therapeutics
Cidara Therapeutics is a biotechnology company focused on developing targeted immunotherapies to improve outcomes for patients with serious diseases. The company emphasizes its Cloudbreak platform, which creates drug-Fc conjugates by attaching targeted small molecules and peptides to a human antibody fragment to engage both disease targets and the immune system. Its pipeline includes clusters in immuno-oncology and influenza, reflecting a focus on therapies that combine precision targeting with immune engagement, and the company is headquartered in San Diego, California.
Recent News
Marker Therapeutics Inc (MRKR) Q1 2026 Earnings Call Transcript
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Report Says MSD Is in Talks to Buy Revolution Meds
Free Cash Flow Investing: Why VFLO Holds Merck Amid Healthcare Headwinds
Merck Bats Away ‘Modest Growth’ Accusations, Touts Broad Pipeline
Merck to Complete Acquisition of Cidara Therapeutics
Merck (MRK) Tops Quarterly Sales Forecasts as Keytruda Drives Growth